Prognostic classification of breast cancer and gene expression profiling;Classification pronostique du cancer du sein et profils d'expression génique sur puces à ADN

Medecine/Sciences

Volumn 24, Issue 6-7, 2008, Pages 599-606

  Bertucci, François ^a   Finetti, Pascal ^a   Cervera, Nathalie ^a   Birnbaum, Daniel ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; COMBINATION CHEMOTHERAPY; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; HUMAN; MOLECULAR TYPING; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TAXONOMY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; BREAST TUMOR; CLASSIFICATION; FEMALE; GENETICS; MORTALITY; SURVIVAL; SURVIVOR;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVORS;

EID: 47749153396     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20082467599     Document Type: Review

References (51)

1. The Chipping Forecast. Nat Genet 1999 ; 21 (suppl) : 1-60.
2. Bertucci F, Houlgatte R, Nguyen C, et al. Gene expression profiling of cancer by use of DNA arrays : how far from the clinic? Lancet Oncol 2001 ; 2 : 674-82.
3. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000 ; 406 : 747-52.
4. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001 ; 98 : 10869-74.
5. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 2006 ; 295 : 2492-502.
6. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003 ; 100 : 8418-23.
7. Yu K, Lee CH, Tan PH, Tan P. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res 2004 ; 10 : 5508-17.
8. Bertucci F, Finetti P, Rougemont J, et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 2005 ; 65 : 2170-8.
9. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005 ; 11 : 5678-85.
10. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 ; 415 : 530-6.
11. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005 ; 365 : 671-9.
12. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002 ; 347 : 1999-2009.
13. Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006 ; 98 : 1183-92.
14. Foekens JA, Atkins D, Zhang Y, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006 ; 24 : 1665-71.
15. Desmedt C, Piette F, Loi S, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007 ; 13 : 3207-14.
16. Piccart-Gebhart MJ. Moving away from the «one shoe fits all» strategy : the key to future progress in chemotherapy. J Clin Oncol 2005 ; 23 : 1611-3.
17. Bertucci F, Houlgatte R, Benziane A, et al. Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet 2000 ; 9 : 2981-91.
18. Bertucci F, Nasser V, Granjeaud S, et al. Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. Hum Mol Genet 2002 ; 11 : 863-72.
19. Pawitan Y, Bjohle J, Amler L, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy : derived and validated in two population-based cohorts. Breast Cancer Res 2005 ; 7 : R953-64.
20. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004 ; 5 : 607-16.
21. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004 ; 351 : 2817-26.
22. Mamounas EP, Fisher B. Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Semin Oncol 2001 ; 28 : 389-99.
23. Bertucci F, Finetti P, Rougemont J, et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 2004 ; 64 : 8558-65.
24. Folgueira MA, Carraro DM, Brentani H, et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 2005 ; 11 : 7434-43.
25. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003 ; 362 : 362-9.
26. Chang JC, Wooten EC, Tsimelzon A, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005 ; 23 : 1169-77.
27. Iwao-Koizumi K, Matoba R, Ueno N, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005 ; 23 : 422-31.
28. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004 ; 22 : 2284-93.
29. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005 ; 23 : 7265-77.
30. Hannemann J, Oosterkamp HM, Bosch CA, et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2005 ; 23 : 3331-42.
31. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006 ; 24 : 4236-44.
32. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004 ; 11 : 643-58.
33. Jansen MP, Foekens JA, van Staveren IL, et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005 ; 23 : 732-40.
34. Chang HY, Sneddon JB, Alizadeh AA, et al. Gene expression signature of fibroblast serum response predicts human cancer progression : similarities between tumors and wounds. PLoS Biol 2004 ; 2 : E7.
35. Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005 ; 102 : 3738-43.
36. Chi JT, Wang Z, Nuyten DS, et al. Gene expression programs in response to hypoxia : cell type specificity and prognostic significance in human cancers. PLoS Med 2006 ; 3 : e47.
37. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005 ; 115 : 1503-21.
38. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007 ; 356 : 217-26.
39. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006 ; 439 : 353-7.
40. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer : understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006 ; 98 : 262-72.
41. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007 ; 25 : 1239-46.
42. Ivshina AV, George J, Senko O, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006 ; 66 : 10292-301.
43. Miller LD, Smeds J, George J, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005 ; 102 : 13550-5.
44. Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007 ; 99 : 147-57.
45. Shi L, Reid LH, Jones WD, et al. The microarray quality control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006 ; 24 : 1151-61.
46. Ein-Dor L, Kela I, Getz G, Givol D, Domany E. Outcome signature genes in breast cancer : is there a unique set? Bioinformatics 2005 ; 21 : 171-8.
47. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006 ; 355 : 560-9.
48. Blay JY. Le futur des thérapeutiques ciblées en oncologie : trouver les cibles, traiter tôt et au long cours. Med Sci (Paris) 2007 ; 23 : 1073-4.
49. Charafe-Jauffret E, Chaffanet M, Bertucci F, et al. Les cancers du sein : vers un modèle cellulaire et moléculaire intégré. Med Sci (Paris) 2007 ; 23 : 626-32.
50. Jordan B. Chroniques génomiques : des puces ADN en clinique ? Med Sci (Paris) 2007 ; 23 : 210-4.
51. Michiels S, Hill C. Défis statistiques posés par les biopuces : autant d'espoir que de faux positifs ? Med Sci (Paris) 2008 ; 24 : 317-9.